From the CDC website:"There are no FDA-approved vaccines or therapeutics available for prevention, post-exposure, or treatment for Ebola virus infection(EVD). Clinical management of EVD should focus on supportive care of complications, such as hypovolemia, electrolyte abnormalities, hematologic abnormalities, refractory shock, hypoxia, hemorrhage, septic shock, multi-organ failure, and disseminated intravascular coagulopathy."
The good news is that clinical trials are underway for experimental vaccines against the Ebola virus. Several news outlets are reporting optimism amongst some of the researchers. The New England Journal reported in their latest issue that volunteers administered with Glaxo's vaccine have all shown an immune response. Thus, they are capable of producing antibodies against the Ebola virus. This is a positive step in preventing future infections from the Ebola virus.